Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?


Demirturk N., AYGEN B., Celik I., Mistik R., AKHAN S., Barut S., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.32, sa.2, ss.155-163, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5152/tjg.2020.19569
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.155-163
  • Anahtar Kelimeler: Chronic hepatitis C, sofosbuvir, ledipasvir, sustained virological response, genotype, real-world data, SOFOSBUVIR PLUS RIBAVIRIN, GENOTYPE 1 INFECTION, TREATMENT-NAIVE, ANTIVIRAL THERAPY, HCV INFECTION, OPEN-LABEL, LEDIPASVIR, SAFETY, LEDIPASVIR/SOFOSBUVIR
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice.